Opthamology @Point of Care Podcasts

S1E5 - Ophthalmology Morning Commute : Optimizing Second-Generation Anti-VEGF Agents for nAMD

25 min · 7 de jul de 2026
Portada del episodio S1E5 - Ophthalmology Morning Commute : Optimizing Second-Generation Anti-VEGF Agents for nAMD

Descripción

Are you ready to rethink your neovascular age-related macular degeneration (nAMD) management strategies? New agents and evolving indications are rapidly reshaping the treatment landscape for nAMD. Join Dr. Diana Do and Dr. Deepak Sambhara for a discussion of clinical trial data and real-world evidence supporting the use of second-generation anti-vascular endothelial growth factor therapies in patients with nAMD. Visit Optimizing Second-Generation Anti-VEGF Agents for nAMD [https://suitehome.atpointofcare.com/library/2707.01/page/0?subdomain=dr\&time=1336000\&pre=skip\&utm_source=podcast] to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. This podcast is powered by Pinecast [https://pinecast.com].

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Opthamology @Point of Care Podcasts!

Empezar

2 meses por 1 €

Después 4,99 € / mes · Cancela cuando quieras

  • Podcasts exclusivos
  • 20 horas de audiolibros / mes
  • Podcast gratuitos

Todos los episodios

8 episodios

Portada del episodio S1E5 - Ophthalmology Morning Commute : Optimizing Second-Generation Anti-VEGF Agents for nAMD

S1E5 - Ophthalmology Morning Commute : Optimizing Second-Generation Anti-VEGF Agents for nAMD

Are you ready to rethink your neovascular age-related macular degeneration (nAMD) management strategies? New agents and evolving indications are rapidly reshaping the treatment landscape for nAMD. Join Dr. Diana Do and Dr. Deepak Sambhara for a discussion of clinical trial data and real-world evidence supporting the use of second-generation anti-vascular endothelial growth factor therapies in patients with nAMD. Visit Optimizing Second-Generation Anti-VEGF Agents for nAMD [https://suitehome.atpointofcare.com/library/2707.01/page/0?subdomain=dr\&time=1336000\&pre=skip\&utm_source=podcast] to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. This podcast is powered by Pinecast [https://pinecast.com].

7 de jul de 202625 min
Portada del episodio S1E4 - Ophthalmology Morning Commute : Precision Vision: Developing Expertise in Retinopathy of Prematurity

S1E4 - Ophthalmology Morning Commute : Precision Vision: Developing Expertise in Retinopathy of Prematurity

Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide. With rapidly evolving screening protocols and treatment advances, timely intervention can significantly improve outcomes. Join Dr. Emily Eton and Dr. Brittni Scruggs as they discuss ROP classification, screening, treatment, and follow-up. Visit Precision Vision: Developing Expertise in Retinopathy of Prematurity [https://suiteweb.atpointofcare.com/#library/ophthalmology/2708.01/page/0]   to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. This podcast is powered by Pinecast [https://pinecast.com].

22 de abr de 202627 min